Edition:
United Kingdom

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

10.77USD
12 Jan 2018
Change (% chg)

-- (--)
Prev Close
$10.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,124
52-wk High
$12.24
52-wk Low
$7.44

Chart for

About

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company's initial product candidates target rare, acute, life-threat... (more)

Overall

Beta: --
Market Cap(Mil.): $340.91
Shares Outstanding(Mil.): 30.85
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 84.57 16.44
EPS (TTM): -- -- --
ROI: -- 3.42 10.61
ROE: -- 5.38 14.21

BRIEF-Edge Therapeutics Says EG-1962 Phase 3 Study Continues As Planned Following Completion Of Futility Analysis

* EDGE'S EG-1962 PHASE 3 NEWTON 2 STUDY CONTINUES AS PLANNED FOLLOWING COMPLETION OF FUTILITY ANALYSIS

29 Dec 2017

BRIEF-Edge Therapeutics reports qtrly loss per share $‍0.37​

* Edge Therapeutics reports third quarter 2017 financial results

01 Nov 2017

BRIEF-Edge Therapeutics appoints Rosemary Crane to Board of Directors

* Edge Therapeutics appoints Rosemary A Crane, pharmaceutical industry leader, to its Board Of Directors

19 Sep 2017

Earnings vs. Estimates